Merck And Cipla Bury Differences To Co-market Raltegravir In India
This article was originally published in PharmAsia News
Executive Summary
Merck agreed to co-market its patented HIV product raltegravir in India with rival Cipla, bringing to end what had started as an attempt for a voluntary license and could have veered toward a compulsory license.